|
1
|
Shukla S, Acharya S and Dulani M: Choroid
melanoma-A rare case report. J Clin Diagn Res. 9:ED09–ED10.
2015.
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Damato B, Eleuteri A, Taktak AF and
Coupland SE: Estimating prognosis for survival after treatment of
choroidal melanoma. Prog Retin Eye Res. 30:285–295. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Aubin JM, Rekman J, Vandenbroucke-Menu F,
Lapointe R, Fairfull-Smith RJ, Mimeault R, Balaa FK and Martel G:
Systematic review and meta-analysis of liver resection for
metastatic melanoma. Br J Surg. 100:1138–1147. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Asadi S, Vaez-Zadeh M, Masoudi SF, Rahmani
F, Knaup C and Meigooni AS: Gold nanoparticle-based brachytherapy
enhancement in choroidal melanoma using a full Monte Carlo model of
the human eye. J Appl Clin Med Phys. 16:55682015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yan F, Wang M, Li J, Cheng H, Su J, Wang
X, Wu H, Xia L, Li X, Chang HC and Li Q: Gambogenic acid induced
mitochondrial-dependent apoptosis and referred to phospho-Erk1/2
and phospho-p38 MAPK in human hepatoma HepG2 cells. Environ Toxicol
Pharmacol. 33:181–190. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lu GB, Yang XX and Huang QS: Isolation and
structure of neo-gambogic acid from Gamboge (Garcinia hanburryi).
Yao Xue Xue Bao. 19:636–639. 1984.In Chinese. PubMed/NCBI
|
|
8
|
Wang X and Chen W: Gambogic acid is a
novel anti-cancer agent that inhibits cell proliferation,
angiogenesis and metastasis. Anticancer Agents Med Chem.
12:994–1000. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Qu BX: The experimental studies on
antineoplastic action of gambogic II. Chinese J Clin Oncol.
1:0211991.
|
|
10
|
Li Q, Cheng H, Zhu G, Yang L, Zhou A, Wang
X, Fang N, Xia L, Su J, Wang M, et al: Gambogenic acid inhibits
proliferation of A549 cells through apoptosis-inducing and cell
cycle arresting. Biol Pharm Bull. 33:415–420. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu XJ, Han QB, Wen ZS, Ma L, Gao J and
Zhou GB: Gambogenic acid induces G1 arrest via GSK3β-dependent
cyclin D1 degradation and triggers autophagy in lung cancer cells.
Cancer Lett. 322:185–194. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen HB, Zhou LZ, Mei L, Shi XJ, Wang XS,
Li QL and Huang L: Gambogenic acid-induced time- and dose-dependent
growth inhibition and apoptosis involving Akt pathway inactivation
in U251 glioblastoma cells. J Nat Med. 66:62–69. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang X, Wang M, Cheng H, Su JJ and Li QL:
Effect of gambogenic acid on apoptosis of melanoma cell line B16. J
Anhui Traditional Chinese Med College. 1:0202013. View Article : Google Scholar
|
|
14
|
Nogami H, Hiraoka Y and Aiso S: Estradiol
and corticosterone stimulate the proliferation of a GH cell line,
MtT/S: Proliferation of growth hormone cells. Growth Horm IGF Res.
29:33–38. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Luo J, Manning BD and Cantley LC:
Targeting the PI3K-Akt pathway in human cancer: Rationale and
promise. Cancer Cell. 4:257–262. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hennessy BT, Smith DL, Ram PT, Lu Y and
Mills GB: Exploiting the PI3K/AKT pathway for cancer drug
discovery. Nat Rev Drug Discov. 4:988–1004. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lejeune FJ, Rimoldi D and Speiser D: New
approaches in metastatic melanoma: Biological and molecular
targeted therapies. Expert Rev Anticancer Ther. 7:701–713. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Robertson GP: Functional and therapeutic
significance of Akt deregulation in malignant melanoma. Cancer
Metastasis Rev. 24:273–285. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chang F, Lee JT, Navolanic PM, Steelman
LS, Shelton JG, Blalock WL, Franklin RA and McCubrey JA:
Involvement of PI3K/Akt pathway in cell cycle progression,
apoptosis, and neoplastic transformation: A target for cancer
chemotherapy. Leukemia. 17:590–603. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fatrai S, Elghazi L, Balcazar N,
Cras-Méneur C, Krits I, Kiyokawa H and Bernal-Mizrachi E: Akt
induces beta-cell proliferation by regulating cyclin D1, cyclin D2,
and p21 levels and cyclin-dependent kinase-4 activity. Diabetes.
55:318–325. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Davies MA: The role of the PI3K-AKT
pathway in melanoma. Cancer J. 18:142–147. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: At the crossroads of development
and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Thompson EW, Newgreen DF and Tarin D:
Carcinoma invasion and metastasis: A role for
epithelial-mesenchymal transition? Cancer Res. 65:5991–5995. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Caramel J, Papadogeorgakis E, Hill L,
Browne GJ, Richard G, Wierinckx A, Saldanha G, Osborne J,
Hutchinson P, Tse G, et al: A switch in the expression of embryonic
EMT-inducers drives the development of malignant melanoma. Cancer
Cell. 24:466–480. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fenouille N, Tichet M, Dufies M, Pottier
A, Mogha A, Soo JK, Rocchi S, Mallavialle A, Galibert MD, Khammari
A, et al: The epithelial-mesenchymal transition (EMT) regulatory
factor SLUG (SNAI2) is a downstream target of SPARC and AKT in
promoting melanoma cell invasion. PLoS One. 7:e403782012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Canel M, Serrels A, Frame MC and Brunton
VG: E-cadherin-integrin crosstalk in cancer invasion and
metastasis. Journal of cell science. 126:393–401. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Satelli A and Li S: Vimentin in cancer and
its potential as a molecular target for cancer therapy. Cellular
and Molecular Life Science. 68:3033–3046. 2011. View Article : Google Scholar
|
|
29
|
Li M, Zhang B, Sun B, Wang X, Ban X, Sun
T, Liu Z and Zhao X: A novel function for vimentin: The potential
biomarker for predicting melanoma hematogenous metastasis. J Exp
Clin Cancer Res. 29:1092010. View Article : Google Scholar : PubMed/NCBI
|
